Charles M. Nichols

Charles M. Nichols

Auto-generated profile, based on publicly available information

Charles M. Nichols

AOA Dx, Denver, Colorado

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2013 in The Journal of Physical Chemistry A
Verified
Journal Article
Closed access
DTDitte L. Thomsen
Ditte L. Thomsen
JRJennifer N. Reece
Jennifer N. Reece
CNCharles M. Nichols
Charles M. Nichols
SHSteen Hammerum
Steen Hammerum
VBVeronica M. Bierbaum
Veronica M. Bierbaum

15 March 2018 in The Analyst
Verified
Journal Article
Closed access
PDF file
CNCharles M. Nichols
Charles M. Nichols
JMJody C. May
Jody C. May
SSStacy D. Sherrod
Stacy D. Sherrod
JMJohn McLean
John McLean
This work presents a fully automated method to generate absolute Collision Cross Sections for annotated libraries.

1 January 2021 in Journal of Lipid Research
Verified
Journal Article
Open access
JBJamal M. Bryant
Jamal M. Bryant
MMM. Merced Malabanan
M. Merced Malabanan
BVBoden H. Vanderloop
Boden H. Vanderloop
CNCharles M. Nichols
Charles M. Nichols
ZHZeinab Haratipour
Zeinab Haratipour
RBRaymond Blind
Raymond Blind
Nuclear receptors are transcription factors that bind lipids, an event that induces a structural conformation of the receptor that favors interaction with transcriptional coactivators. The nuclear receptor steroidogenic factor-1 (SF-1, NR5A1) binds the signaling phosphoinositides PI(4,5)P2 (PIP2) and PI(3,4,5)P3 (PIP3), and our previous crystal structures showed how the phosphoinositide headgroups regulate SF-1 function. However, what role the acyl chains play in regulating SF-1 structure remains unaddressed. Here, we used X-ray crystallography with in vitro binding and functional assays to examine how the acyl chains of PIP3 regulate human SF-1 ligand-binding domain structure and function. Altering acyl chain length and unsaturation regulates apparent binding of all tested phosphoinositides to SF-1. Mass spectrometry-based lipidomics data suggest C16 and C18 phospholipids preferentially associate with SF-1 expressed ectopically in bacteria. We then solved the 2.5 Å crystal structure of SF-1 bound to dioleoyl PIP3(18:1/18:1) to compare it with a matched structure of SF-1 bound to dipalmitoyl PIP3(16:0/16:0). The dioleoyl-bound structure was severely disordered in a specific SF-1 region associated with pathogenic human polymorphisms and within the coactivator-binding region critical for SF-1 function while inducing increased sensitivity to protease digestion in solution. Validating these structural observations, in vitro functional studies showed dioleoyl PIP3 induced 6-fold poorer affinity of a peroxisome proliferator-activated receptor gamma coactivator 1-alpha coactivator peptide for SF-1 compared with dipalmitoyl PIP3. Together, these data suggest the chemical nature of the phosphoinositide acyl chains controls the ordered state of specific, clinically important structural regions in SF-1, regulating SF-1 function in vitro.

1 April 2012 in International Journal of Mass Spectrometry
Verified
Journal Article
Closed access
JGJohn M. Garver
John M. Garver
ZYZhibo Yang
Zhibo Yang
CNCharles M. Nichols
Charles M. Nichols
BWBenjamin B. Worker
Benjamin B. Worker
SGScott Gronert
Scott Gronert
VBVeronica M. Bierbaum
Veronica M. Bierbaum

13 August 2019 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Closed access
CNCharles M. Nichols
Charles M. Nichols
ZWZhe-Chen Wang
Zhe-Chen Wang
WLW. Carl Lineberger
W. Carl Lineberger
VBVeronica M. Bierbaum
Veronica M. Bierbaum

2 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
NKNathan Kaiser
Nathan Kaiser
MSMaximillian Steers
Maximillian Steers
CNCharles M. Nichols
Charles M. Nichols
HMHestia S. Mellert
Hestia S. Mellert
GPGary Pestano
Gary Pestano
A major hurdle for blood-based proteomic diagnostics is efficient transport of specimens from the collection site to the testing laboratory. Dried blood spots have shown utility for diagnostic applications, specifically those where red blood cell hemolysis and contamination of specimens with hemoglobin is not confounding. Conversely, applications that are sensitive to the presence of the hemoglobin subunits require blood separation, which relies on centrifugation to collect plasma/serum, and then cold-chain custody during shipping. All these factors introduce complexities and potentially increased costs. Here we report on a novel whole blood-collection device (BCD) that efficiently separates the liquid from cellular components, minimizes hemolysis in the plasma fraction, and maintains protein integrity during ambient transport. The simplicity of the design makes the device ideal for field use. Whole blood is acquired through venipuncture and applied to the device with an exact volume pipette. The BCD design was based on lateral-flow principles in which whole blood was applied to a defined area, allowing two minutes for blood absorption into the separation membrane, then closed for shipment. The diagnostic utility of the device was further demonstrated with shipments from multiple sites (n = 33) across the U.S. sent to two different centralized laboratories for analyses using liquid chromatography/mass spectrometry (LC/MS/MS) and matrix assisted laser desorption/ionization-time of flight (MALDI-ToF) commercial assays. Specimens showed high levels of result label concordance for the LC/MS/MS assay (Negative Predictive Value = 98%) and MALDI-ToF assay (100% result concordance). The overall goal of the device is to simplify specimen transport to the laboratory and produce clinical test results equivalent to established collection methods.